- Home
- CNOB vs STOK Comparison
CNOB vs STOK Comparison
Compare CNOB & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- STOK
- Stock Information
- Founded
- CNOB 1982
- STOK 2014
- Country
- CNOB United States
- STOK United States
- Employees
- CNOB N/A
- STOK N/A
- Industry
- CNOB Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- STOK Health Care
- Exchange
- CNOB Nasdaq
- STOK Nasdaq
- Market Cap
- CNOB 1.3B
- STOK 1.3B
- IPO Year
- CNOB 1996
- STOK 2019
- Fundamental
- Price
- CNOB $24.42
- STOK $34.34
- Analyst Decision
- CNOB Buy
- STOK Strong Buy
- Analyst Count
- CNOB 1
- STOK 7
- Target Price
- CNOB $31.00
- STOK $30.83
- AVG Volume (30 Days)
- CNOB 274.5K
- STOK 1.5M
- Earning Date
- CNOB 10-30-2025
- STOK 11-12-2025
- Dividend Yield
- CNOB 2.97%
- STOK N/A
- EPS Growth
- CNOB N/A
- STOK N/A
- EPS
- CNOB 0.80
- STOK 0.91
- Revenue
- CNOB $241,854,000.00
- STOK $199,893,000.00
- Revenue This Year
- CNOB $50.62
- STOK $416.54
- Revenue Next Year
- CNOB $28.54
- STOK N/A
- P/E Ratio
- CNOB $30.44
- STOK $38.19
- Revenue Growth
- CNOB N/A
- STOK 1218.82
- 52 Week Low
- CNOB $20.61
- STOK $5.35
- 52 Week High
- CNOB $29.31
- STOK $38.69
- Technical
- Relative Strength Index (RSI)
- CNOB 46.54
- STOK 77.38
- Support Level
- CNOB $23.25
- STOK $32.65
- Resistance Level
- CNOB $24.79
- STOK $35.19
- Average True Range (ATR)
- CNOB 0.83
- STOK 2.60
- MACD
- CNOB -0.17
- STOK 0.35
- Stochastic Oscillator
- CNOB 36.00
- STOK 71.59
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.